

Application No. 10/761,596
Amendment dated January 24, 2005
Reply to Office Action of September 22, 2004

FILED
CENTRAL INDEX CENTER

JAN 24 2005

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-8 (cancelled)

9. (currently amended) A pharmaceutical composition useful in increasing insulin sensitivity in
~~to cause an increase in nitric oxide in the liver~~ a patient in need thereof, said composition
comprising a nitric oxide donor compound and a pharmaceutically acceptable carrier, wherein
said composition is structurally modified to preferentially release nitric oxide in the liver.

10. (currently amended) A pharmaceutical composition useful in increasing insulin sensitivity
in a mammalian patient in need thereof, said composition comprising an effective amount of a
nitric oxide agonist, and a pharmaceutically acceptable carrier, wherein said composition is
structurally modified to preferentially release nitric oxide in the liver.

11. (currently amended) A kit comprising in combination:

a) a composition comprising at least one of a nitric oxide donor or a nitric oxide
agonist and a pharmaceutically acceptable carrier, wherein said composition is structurally
modified to preferentially release nitric oxide in the liver; and;

b) instructions for the administration of said nitric oxide donor or nitric oxide agonist
administering the composition to ameliorate the symptoms of insulin resistance.

12. (previously presented) The kit of claim 11 comprising a nitric oxide donor.

13. (previously presented) The kit of claim 11 comprising a nitric oxide agonist.

Application No. 10/761,596
Amendment dated January 24, 2005
Reply to Office Action of September 22, 2004

14. (new) The pharmaceutical composition according to claim 9 or 10, wherein said insulin sensitivity is hepatic insulin sensitizing substance (HISS) dependent insulin sensitivity.

15. (new) The kit according to claim 11, wherein said insulin sensitivity is HISS dependent insulin sensitivity.

16. (new) The kit of claim 11, comprising a nitric oxide donor and a nitric oxide agonist.